Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days

References

• Nosek M, Kennedy H, Beyene Y, et al. The effects of perceived stress and attitudes toward menopause and aging on symptoms of menopause. J Midwifery Womens Health 2010;55:328–34
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Gass MLS, Manson JAE, Cosman F, et al. The North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Advisory Panel. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Ghazal S, Pal L. Perspective of hormone therapy 10 years after WHI. Maturitas 2013;76:208--12
   PubMed Web of Science ®Google Scholar
• Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. Fertil Steril 2005;84:1589–601
   PubMed Web of Science ®Google Scholar
• Narod SA. Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol 2011;8:669–76
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens – a review of their effects in perimenopausal and postmenopausal women. Drugs Aging 2004;21:865–83
   PubMed Web of Science ®Google Scholar
• Perez-Campos EF. Ethinylestradiol/dienogest in oral contraception. Drugs 2010;70:681–9
   PubMed Web of Science ®Google Scholar
• Endrikat J, Graeser T, Mellinger U, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women. Maturitas 2007;58:201–7
   PubMed Web of Science ®Google Scholar
• Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Women’s Health (Lond Engl) 2010;6:27–35
   PubMedGoogle Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynaecol Obstet 2012;117:228–33
   PubMed Web of Science ®Google Scholar
• Oettel M, Gräser T, Hoffmann H, et al. The preclinical and clinical profile of dienogest. A short overview. Drugs Today 1999;35:3–12
   Web of Science ®Google Scholar
• Medicinal Products Act in the version published on 12 December 2005 (Federal Law Gazette [BGBl.]) Part I, p. 3394, last amended by Article 1 of the Law of 19 October 2012 (Federal Law Gazette I p. 2192). Available from: http://www.gesetze-im-internet.de/englisch_amg/englisch_amg.html#p0073 [last accessed 28 May 2014]
   Google Scholar
• Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung, Durchführung und Auswertung von Anwendungsbeobachtungen [Recommendations of the Federal Institute for Drugs and Medical Devices and the Paul-Ehrlich-Institute (Germany) for the planning, accomplishment and evaluation of observational studies]: Available from: http://www.pei.de/SharedDocs/Downloads/pu/klinische-pruefung/100707-awb-kommentierung-fachkreise.pdf;jsessionid=0CE9C17C31690914A9CC0EE49BDFE7F4.1_cid344?__blob=publicationFile&v=1 [last accessed 28 May 2014]
   Google Scholar
• Summary of Product Characteristics: Lafamme® 1 mg/2 mg. Available from: http://www.fachinfo.de/pdf/01/44/014473.pdf [last accessed 23 Jun 2014]
   Google Scholar
• Heinemann LAJ, DoMinh T, Strelow F, et al. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes 2004;2:67--73
   PubMedGoogle Scholar
• von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806--8
   Google Scholar
• Gelfand MM, Moreau M, Ayotte NJ, et al. Clinical assessment and quality of life of postmenopausal women treated with a new intermittent progestogen combination hormone replacement therapy: a placebo-controlled study. Menopause 2003;10:29–36
   PubMed Web of Science ®Google Scholar
• Curran MP, Wagstaff AJ. Estradiol and norgestimate - a review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging 2001;18:863–85
   PubMed Web of Science ®Google Scholar
• Speroff L, Symons J, Kempfert N, Rowan J ( for the FemHRT Study Investigators). The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femHRT®) on the frequency and intensity of vasomotor symptoms. Menopause 2000;7:383–90
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al. Women’s Health Initiative Investigators. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women’s Health Initiative. Obstet Gynecol 2005;105:1063–73
   PubMed Web of Science ®Google Scholar
• Meuwissen JH, Beijers-De Bie L, Vihtamaki T, et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone. Gynecol Endocrinol 2001;15:349–58
   PubMed Web of Science ®Google Scholar
• Gräser T, Römer T, Wiedey KD, Janaud A. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001;4:332–42
   PubMedGoogle Scholar
• von Schoultz B. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment. Climacteric 2003;6:24–32
   PubMedGoogle Scholar
• Schneider HP. Androgens and antiandrogens. Ann NY Acad Sci 2003;997:292–306
   PubMed Web of Science ®Google Scholar
• Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric 2003;Suppl. 2:17–23
   Google Scholar
• Simon JA, Symons JP, FemHRT Study Investigators. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause 2001;8:321–7
   PubMed Web of Science ®Google Scholar
• Micks EA, Jensen JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv Ther 2013;30:1–13
   PubMed Web of Science ®Google Scholar
• Fraser IS, Römer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod 2011;26:2698–708
   PubMed Web of Science ®Google Scholar
• Taffe J, Dennerstein L. Retrospective self-report compared with menstrual diary data prospectively kept during the menopausal transition. Climacteric 2000;3:183–91
   PubMedGoogle Scholar